Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOP-R Followed by Zevalin and Rituxan in Follicular Lymphoma
NCT00177554Phase 2Completed
- Sponsor
- University of Pittsburgh
- Start
- Nov 2003
- Primary completion
- May 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in follicular lymphoma (FL), sponsored by University of Pittsburgh. Primary endpoint: Complete Response Rate. Started Nov 2003; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT00177554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00177554.